Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Wed, 20 Jun 01:30 pm

Indian share markets continued to trade above the dotted line in the last two trading hours. Most of the sectoral indices are trading positive with pharma, capital goods and power stocks being the biggest gainers. Only IT, realty and FMCG are trading in the red.

The BSE-Sensex is trading up 22 points and NSE-Nifty is trading up 9 points. BSE Mid cap index and BSE Small Cap index are trading up by 0.6% each. The rupee is trading at 55.9 to the US dollar.

The automobile stocks are currently trading mixed. Maharashtra Scooters and Eicher Motors are the biggest losers whereas Tata Motors and TVS Motors are the biggest gainers. As per a leading financial daily, the steep differential in petrol and diesel prices is leading to a shift in consumer preference for diesel car variants. Car companies that are already offering incentives and discounts on petrol cars are now cutting their production to prevent inventory pile-up. Maruti Suzuki has said that its petrol car sales are expected to fall by 50,000 units in FY13. Earlier for three days in May and June, the company had shut production of key petrol models namely Alto, Estilo and A-Star. Going forward, the company will shut production for a week starting June 24. The stock is down 0.9%.

General Motors has been observing no-production days for petrol-only models such as Spark, U-VA minis, Optra and Aveo sedans to align production to reduced demand. Similarly, Toyota Kirloskar has stopped production of petrol cars Liva, Etios and Corolla Altis from June 16 onwards. The company's inventory of petrol cars had swelled up to over 30 days.

Majority of the Indian pharma stocks are trading positive with Fresnius Kabi and Indoco Remedies being the biggest gainers. A leading business daily has reported that Daiichi Sankyo Venezuela (DSV), a subsidiary of Daiichi Sankyo and a group company of Ranbaxy Laboratories would start marketing the latter's products in Venezuela. As per the company, this is part of the hybrid business model. Ranbaxy has been marketing products in Venezuela through a local distributor all this while. It is believed that DSV has already started promotion of Ranbaxy's products in the country. This is a positive move for the company considering that DSV would be able to have a better reach given its size. It may be noted that Venezuela is the third largest pharmaceutical market in Latin America. While DSV has established presence with some of the parent's key products, it would now also focus on expanding Ranbaxy's portfolio of medicines.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.